$-0.50 EPS Expected for MyoKardia, Inc. (MYOK)

September 30, 2018 - By Vernon Prom

MyoKardia, Inc. (NASDAQ:MYOK) Logo

Analysts expect MyoKardia, Inc. (NASDAQ:MYOK) to report $-0.50 EPS on November, 1.They anticipate $0.08 EPS change or 19.05 % from last quarter’s $-0.42 EPS. After having $-0.49 EPS previously, MyoKardia, Inc.’s analysts see 2.04 % EPS growth. The stock increased 0.93% or $0.6 during the last trading session, reaching $65.2. About 237,737 shares traded. MyoKardia, Inc. (NASDAQ:MYOK) has risen 39.18% since September 30, 2017 and is uptrending. It has outperformed by 23.56% the S&P500.

MyoKardia, Inc., a clinical stage biopharmaceutical company, engages in discovering, developing, and commercializing therapies for the treatment of serious and neglected rare cardiovascular diseases. The company has market cap of $2.62 billion. The Company’s lead product candidate is MYK-461, an orally-administered small molecule that is in Phase II clinical trials designed to reduce excessive cardiac muscle contractility leading to hypertrophic cardiomyopathy . It currently has negative earnings. The firm also develops MYK-491, an orally-administered small molecule that treats genetic dilated cardiomyopathy (DCM) by restoring normal contractility in the diseased DCM heart.

More important recent MyoKardia, Inc. (NASDAQ:MYOK) news were published by: Seekingalpha.com which released: “Premarket analyst action – healthcare” on September 28, 2018, also Streetinsider.com published article titled: “Citi Starts MyoKardia (MYOK) at Buy”, Benzinga.com published: “The Daily Biotech Pulse: Advaxis Posts Narrower Loss, Endocyte Announces $175M Offering, Leadership Transition At …” on September 11, 2018. More interesting news about MyoKardia, Inc. (NASDAQ:MYOK) was released by: Globenewswire.com and their article: “MyoKardia to Present at the 2018 Cantor Global Healthcare Conference” with publication date: September 22, 2018.

MyoKardia, Inc. (NASDAQ:MYOK) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: